ArticleCureus2025
Impact of Gastrointestinal Symptoms on Quality of Life in Individuals With Chronic Kidney Disease in Cameroon: A Hospital-Based Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Gastrointestinal symptoms (GIS) are commonly reported in individuals with chronic kidney disease (CKD) and can significantly impact quality of life (QoL). Despite this, data from sub-Saharan Africa remain scarce. This study aimed to evaluate the effect of GIS on QoL in CKD patients in Cameroon. Materials and methods A cross-sectional study was carried out between December 2021 and May 2022 at the Yaounde General Hospital and Yaounde University Teaching Hospital. Participants included adults (≥18 years) with CKD stages III-V or on hemodialysis. GIS were assessed using a Modified Rome IV Diagnostic Questionnaire, and QoL was measured with the Gastrointestinal Quality of Life Index (GIQLI). Associations and correlations between GIS, QoL, and clinical characteristics were analyzed using Spearman's correlation and multiple regression, with significance set at p<0.05. Results Among 202 participants (median age 58 years, 63.4% male), 82.2% reported at least one GIS. The most common symptoms were anorexia (41.1%), constipation (39.6%), nausea (36.6%), bloating (33.7%), and vomiting (32.2%). QoL showed a weak negative correlation with serum creatinine (rho=-0.36; p<0.001) and a weak positive correlation with estimated glomerular filtration rate (eGFR) (rho=0.40; p<0.001). GIS and hypertension were significantly associated with lower QoL scores. Specifically, the presence of GIS (aOR=0.17; CI: 0.06-0.40; p<0.001) and hypertension (aOR=0.35; CI: 0.13-0.85; p=0.02) reduced the odds of better QoL. Conclusion GIS are prevalent among CKD patients in Cameroon and are linked to diminished QoL. Reduced renal function and hypertension further compound this effect. Routine QoL assessments and symptom-targeted interventions should be integrated into clinical care to enhance patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.